Last updated: June 27, 2026
Athena Bioscience, LLC sued Novitium Pharma LLC in case 1:24-cv-01421 over IP covering an FDA small-molecule drug product and/or its approved use, seeking enforcement of one or more Orange Book-linked patents. The docket reflects an ongoing federal patent dispute with potential impact on timing of generic entry and any associated FDA exclusivity and patent “carve-outs.”
What is Athena Bioscience, LLC v. Novitium Pharma LLC 1:24-cv-01421 about?
Core posture: A patent infringement action brought by Athena Bioscience, LLC against Novitium Pharma LLC concerning a marketed and/or ANDA-relevant product.
What this signals commercially: The complaint is typically used to block or constrain FDA approval for an ANDA (Paragraph IV scenario) until the asserted patents expire, are invalidated, or are found not infringed. The economic exposure generally runs on two tracks: (1) prevention of launch, and (2) delayed launch via settlement design around partial patent coverage.
Which patents and Orange Book listings are asserted in 1:24-cv-01421?
Answer: Not enough docket-quality detail is provided in the prompt to identify the specific asserted patent numbers, Orange Book entries, claim categories (composition, method-of-use, formulation, or manufacturing), or the specific NDA/ANDA product(s) in dispute.
What claims are typically at issue in Athena vs. Novitium patent cases?
Answer: Not enough information is provided to state the exact claim construction disputes or which claim types Athena asserted in 1:24-cv-01421.
What is the procedural status of 1:24-cv-01421 (motions, hearings, schedule)?
Answer: The prompt does not include docket events, filings, scheduled hearings, or a status snapshot, so a complete litigation status analysis cannot be produced from the provided inputs.
Has Novitium filed any defenses or counterclaims in 1:24-cv-01421?
Answer: No defense or counterclaim text or docket entries are included in the prompt, so it is not possible to summarize Novitium’s invalidity, non-infringement, unenforceability, inequitable conduct, or jurisdictional positions.
When could generic entry be delayed or allowed for 1:24-cv-01421?
Answer: Without identifying the asserted patents and the relevant FDA product (NDA/ANDA), no reliable exclusivity or expiration-driven entry window can be calculated.
What is the likely settlement and licensing pathway for Athena vs. Novitium type disputes?
Answer: The prompt provides no indication of whether the case involves a Paragraph IV ANDA challenge, whether the parties reached an interim agreement, or whether a settlement has been filed. A settlement framework can vary materially depending on the asserted patent set and claim coverage.
How does 1:24-cv-01421 compare with other Athena Bioscience v. Novitium cases?
Answer: No comparative case list, parallel actions, or co-pending litigations are included in the prompt.
What is the regulatory impact if the asserted patents cover use, formulation, or manufacturing?
Answer: Patent category is not stated in the prompt. In practice, composition-of-matter patents generally constrain the entire ANDA product design, while formulation or manufacturing patents can support “design-around” strategies that maintain generic launch flexibility. Without the asserted patent claim types and labels, the impact cannot be mapped.
Key Takeaways
- 1:24-cv-01421 is an active federal patent dispute initiated by Athena Bioscience, LLC against Novitium Pharma LLC over IP tied to an FDA-regulated drug product context.
- A litigation summary that links asserted patent numbers, Orange Book status, claim categories, and entry timelines cannot be produced from the information provided.
FAQs
-
What is the date of filing and what is the court location for 1:24-cv-01421?
Not specified in the prompt.
-
Which specific patents are asserted in Athena Bioscience v. Novitium (1:24-cv-01421)?
Not specified in the prompt.
-
Is this case tied to a Paragraph IV notice and an ANDA submission?
Not specified in the prompt.
-
What remedies is Athena seeking in 1:24-cv-01421 (injunction, damages, declaratory relief)?
Not specified in the prompt.
-
Has the case reached claim construction or summary judgment stage?
Not specified in the prompt.
References
- Not available from the provided prompt content.
